Loading…
Precision BioSciences, Inc. is projected to rise to $14.57 by 2027, a +66% move from its current price of $8.76. DTIL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $8.43 | $8.77 | $9.11 | +0.06% |
| Jul 13 | $8.30 | $8.77 | $9.27 | +0.12% |
| Jul 14 | $8.20 | $8.78 | $9.39 | +0.18% |
| Jul 15 | $8.12 | $8.78 | $9.49 | +0.24% |
| Jul 16 | $8.05 | $8.79 | $9.58 | +0.30% |
| Jul 17 | $7.99 | $8.79 | $9.67 | +0.36% |
| Jul 18 | $7.94 | $8.80 | $9.75 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.94 | $8.80 | $9.75 | +0.42% |
| Week 2 | $7.64 | $8.83 | $10.22 | +0.85% |
| Week 3 | $7.42 | $8.87 | $10.60 | +1.28% |
| Week 4 | $7.25 | $8.91 | $10.95 | +1.71% |
| Week 5 | $7.11 | $8.95 | $11.26 | +2.14% |
| Week 6 | $6.98 | $8.99 | $11.56 | +2.58% |
| Week 7 | $6.87 | $9.02 | $11.85 | +3.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion.
DTIL is the stock ticker for Precision BioSciences, Inc. It is currently priced at $9.25 and has a market cap of $238.67M. It ranks 3698.
The 30-day technical picture is bullish, with RSI14 at 80, SMA50 at $7.18, and SMA200 at $5.80. The stock shows a near-term support at $6.04 and resistance at $9.25. The 30-day price range runs from $7.04 to $12.15, and annualized volatility is 80%.
These indicators frame a price outlook that features multi-year upside, guided by forecasted averages across 2026 to 2050, including an average of $21.72 in 2030 and $178.14 in 2050, with a max of $392.65 in 2050 and a min of $3.57 in 2026.
A major floor 50.3% below — a decisive break under it would weaken the trend.
The nearest floor, 31.1% below — buyers have tended to step in here.
The nearest ceiling, 5.9% above — a clean break opens room to run.
A major ceiling 28.6% above — clearing it would confirm fresh momentum.
Key DTIL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DTIL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.94 | Sell | $8.81 | Sell |
| MA 10 | $8.38 | Buy | $8.41 | Buy |
| MA 20 | $7.47 | Buy | $7.88 | Buy |
| MA 50 | $7.30 | Buy | $7.30 | Buy |
| MA 100 | $6.58 | Buy | $6.73 | Buy |
| MA 200 | $5.86 | Buy | $6.23 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.94 | Neutral |
| Stoch RSI (14) | 60.62 | Neutral |
| CCI (20) | 92.51 | Neutral |
| Williams %R (14) | -20.47 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | 26.04 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 79.53 | Neutral |
| TRIX (15) | 0.67 | Buy |
| Awesome (5,34) | 1.72 | Buy |
| Ultimate (7,14,28) | 72.40 | Sell |
| Momentum (10) | 2.01 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 9.43 | Sell |
| ADX (14) | 25.45 | Buy |
| ATR (14) | 0.26 | Info |
The 30-day snapshot shows a bullish tone for near-term price action. The range over the next month runs from $7.04 to $12.15, with the price hovering around a resistance of $9.25 as it tests upside momentum.
The RSI is 80, indicating overbought pressure, while the stock trades above the SMA50 of $7.18 and the SMA200 of $5.80. A defined support is at $6.04, providing a potential floor if near-term pressure increases.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.57 | $8.76 | $13.00 | 0% | Neutral | |
| $11.14 | $14.57 | $20.41 | +66% | Bullish | |
| $11.70 | $15.96 | $23.49 | +82% | Bullish | |
| $13.19 | $18.62 | $28.47 | +113% | Bullish | |
| $14.74 | $21.47 | $33.91 | +145% | Bullish | |
| $14.76 | $22.12 | $35.92 | +153% | Bullish | |
| $18.43 | $28.38 | $47.23 | +224% | Bullish | |
| $22.29 | $35.22 | $59.94 | +302% | Bullish | |
| $26.15 | $42.34 | $73.55 | +383% | Bullish | |
| $32.04 | $53.12 | $94.03 | +506% | Bullish | |
| $43.61 | $80.75 | $154.57 | +822% | Bullish | |
| $81.26 | $180.58 | $386.53 | +19.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.57 | $8.76 | $10.46 | +0.00% |
| August 2026 | $7.53 | $8.99 | $11.10 | +2.66% |
| September 2026 | $7.67 | $9.26 | $11.61 | +2.94% |
| October 2026 | $7.45 | $9.06 | $11.51 | -2.14% |
| November 2026 | $7.55 | $9.25 | $11.88 | +2.14% |
| December 2026 | $8.12 | $10.02 | $13.00 | +8.31% |
Click any year to see its month-by-month DTIL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DTIL to range from $3.57 to $13.00 through 2026. The $8.76 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The DTIL price prediction for 2027 points to an average of $14.57 (low $11.14, high $20.41) — a potential gain of +66% on today's $8.76. Buyers look set to stay in control over this stretch.
In 2028, DTIL is projected to trade between $11.70 and $23.49, averaging $15.96 — a potential gain of +82% from today's $8.76. That is up +10% on the projected 2027 average. Momentum favours further upside here.
Precision BioSciences, Inc.'s 2029 outlook centres on $18.62, within a $13.19 to $28.47 range. That is up +17% on the projected 2028 average. That marks a +113% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, DTIL could reach as high as $33.91, with a base case around $21.47 and support toward $14.74 — roughly +145% from $8.76. Momentum favours further upside here.
Expect DTIL to range from $14.76 to $35.92 through 2031. The $22.12 average target implies a +153% move from current prices. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The DTIL price prediction for 2032 points to an average of $28.38 (low $18.43, high $47.23) — a potential gain of +224% on today's $8.76. Momentum favours further upside here.
In 2033, DTIL is projected to trade between $22.29 and $59.94, averaging $35.22 — a potential gain of +302% from today's $8.76. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Precision BioSciences, Inc.'s 2034 outlook centres on $42.34, within a $26.15 to $73.55 range. That is up +20% on the projected 2033 average. That marks a +383% change versus current levels. Momentum favours further upside here.
By 2035, DTIL could reach as high as $94.03, with a base case around $53.12 and support toward $32.04 — roughly +506% from $8.76. Buyers look set to stay in control over this stretch.
Expect DTIL to range from $43.61 to $154.57 through 2040. The $80.75 average target implies a +822% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The DTIL price prediction for 2050 points to an average of $180.58 (low $81.26, high $386.53) — a potential gain of +19.6x on today's $8.76. Buyers look set to stay in control over this stretch.
Investing $1,000 in DTIL today (≈ 114.155251 DTIL) could be worth
$20,614.18
+$19,614.18 (+1961%) by 2050 · US Dollar
Based on the average projected DTIL price of $180.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DTILwould be worth at today's price.
$1,000 invested in DTIL on Jul 10, 2025 (≈ 207.039341 DTIL) would be worth
$1,813.66
+$813.66 (+81.4%) today · 1.81× · US Dollar
Based on a DTIL entry price of $4.83 vs. today's $8.76.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.18 | $1,070.9 | +7.1% |
| 1 month ago | $6.45 | $1,358.14 | +35.8% |
| 3 months ago | $6.67 | $1,313.34 | +31.3% |
| 6 months ago | $4.06 | $2,157.64 | +115.8% |
| 1 year ago | $4.83 | $1,813.66 | +81.4% |
| All time (5.0y) ago | $343.8 | $25.48 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DTIL forecast.
Our base-case forecast reaches $18.00 around 2029.
Implied market cap at $18.00: $464.44M
The multi-year forecast paints a bullish path from 2027 through 2050. The path includes a steady rise in the average price, with 2030 expected to average $21.72 and 2050 to average $178.14, supported by a maximum forecast of $392.65 and a minimum forecast of $80.17 in 2050. The 2030 forecast shows an average of $21.72 with a max of $34.90 and a min of $14.65, yielding an ROI of 134.8.
By 2040, the average rises to $82.04 with a max of $161.05 and min of $42.55, and ROI of 786.9. By 2050, the average is $178.14 with a max of $392.65 and a min of $80.17, and ROI of 1825.9. These are estimates, not guarantees, and subject to market and regulatory risks.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $21.72 with a min of $14.65 and a max of $34.90; ROI 134.8; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with rising annual averages: 2026 $9.25, 2027 $15.21, 2028 $16.44, 2029 $19.01, 2030 $21.72, 2040 $82.04, 2050 $178.14; ROI values scale to 1825.9. These are estimates and not guarantees.
Yes. The forecast lists 2032 max $49.14 and 2033 max $62.74, meaning the upper bound exceeds $50 in 2033.
Current price $9.25; Market cap $238.67M; Rank 3698.
RSI14 is 80; SMA50 is $7.18; SMA200 is $5.80; Support is $6.04; Resistance is $9.25; 30-day range is $7.04–$12.15; Sentiment is BULLISH.
Precision BioSciences, Inc. Community Discussion
0Share your Precision BioSciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.